On November 25, 2025 Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, reported the successful closure of its Series B1 financing round of $12,908,000. The round was 100% oversubscribed, reflecting strong investor confidence in the company’s proprietary Zeta Platform and its potential to transform breast cancer care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from this round will support the advancement of Zetagen’s lead candidate, ZetaMet (Zeta-BC-003) towards commercialization, accelerate clinical development of ZetaMast (Zeta-MBC-005), and complete preclinical studies & GMP manufacturing of ZetaPrime (Zeta-PBC-007).

"The strong demand in our Series B1 round highlights the promise of our Phase 2a clinical data for ZetaMet in treating metastatic breast cancer to bone," said Joe C. Loy, CEO of Zetagen Therapeutics. "At the core of these encouraging results is our discovery of a novel molecular pathway—triggered by our compounds activating a conserved nuclear receptor—which enables promising predictability in dosing and outcomes from bench to bedside."

Advancing the Zeta Platform
Zetagen’s Zeta Platform is the development of first-of-its-kind therapies for metastatic and primary breast cancer. Our novel approach via proprietary carriers with a singular injection, delivers tumoricidal compounds which minimize severe off-target side effects while increasing survival rates.

The platform includes:
ZetaMet (Zeta-BC-003): Targets metastatic breast cancer in bone, ceasing lytic activity, inhibiting pain, and regenerating new bone, all via a singular intratumoral injection, without systemic limitation, minimizing skeletal related events (fractures). We have completed a Phase 2a clinical trial at the University of British Columbia demonstrated Complete Response in treated lesions, full bone regeneration, and no skeletal-related events. Preliminary results to be presented at the upcoming SABCS conference.
ZetaMast (Zeta-MBC-005): is a novel hydrogel delivering two synergistic tumoricidal agents via a single intratumoral injection for breast cancer liver metastases (BCLM). Designed to localize treatment and reduce systemic toxicity, it has shown promising preclinical results—published in PLOS ONE and co-authored by Dr. Debu Tripathy—demonstrating reduced tumor burden, prevention of soft tissue metastases, and improved survival. A Phase 1b dose-escalation study is planned for 1H-2026.
ZetaPrime (Zeta-PBC-007): a neo-adjuvant treatment engineered for intratumoral administration following diagnosis. Utilizing proprietary hydrogel-like lipid carrier, formulation enables controlled release of 2 small molecules—one being novel molecular entity and or the ability to deliver a CDK4 or CDK4/6 protein inhibitor. Designed for solubility within adipose tissue, approach targets primary breast cancer, aiming to mitigate off-target effects, potentially reducing necessity for lumpectomies and mastectomies, decrease radiation exposure, and enhance patient survival. ZetaPrime’s single-dose in-vivo study showed improved survival and tumor suppression over Tamoxifen and Verzenio in a mouse mammary fat pad model; results will be presented at the upcoming SABCS conference.
Continued Momentum
The Series B1 funding follows a series of strategic milestones for Zetagen, including:

Expansion of the company’s global IP portfolio to 70+issued patents including Composition-of-Matter patents & claims on ZetaMet, ZetaMast, and ZetaPrime
Successful completion of the Phase 2a study of ZetaMet for metastatic breast cancer to bone
Accepted abstracts by SABCS on ZetaMet preliminary clinical results and ZetaPrime in-vivo results of head-to-head comparison towards Verzenio

(Press release, Zetagen Therapeutics, NOV 25, 2025, View Source [SID1234660940])

On November 25, 2025 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported the selection of two abstracts for oral presentation, three abstracts for poster presentation and one abstract for online publication at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held December 6-9, 2025, in Orlando, Florida. BostonGene will exhibit in booth #1581.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research we are presenting highlights the critical need for advanced patient stratification in hematology. Our AI-powered tools, such as the Lymphly classifier and our B-cell-based marker provide the molecular precision required to de-risk clinical programs and ensure the right drug reaches the right patient subpopulation. This is about moving beyond conventional diagnostics to build a foundational, integrated approach for effective companion diagnostics and unified monitoring in drug studies," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the presentations are below:

Oral presentations:

Abstract number: 14219
Title: Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk mantle cell lymphoma: The WINDOW-3 clinical trial
Date & time: December 7 — 5:45 PM – 6:00 PM
Location: Tangerine Ballroom F2
Speaker: Preetesh Jain, MD, DM, PhD, The University of Texas MD Anderson Cancer Center

The WINDOW-3 clinical trial evaluating acalabrutinib plus rituximab followed by brexucabtagene autoleucel CART in patients with high-risk mantle cell lymphoma (MCL) demonstrated strong efficacy and encouraging survival outcomes. BostonGene’s AI-based immunoprofiling revealed CART therapy in high-risk MCL led to drastic immune remodeling, with specific CART-cell types and memory subsets correlating with toxicity, indicating a key role in immune system monitoring for treatment-related toxicities.

Research conducted in collaboration with MD Anderson Cancer Center

Abstract number: 7242
Title: A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas
Date & time: December 8 — 5:00 PM – 5:15 PM
Location: OCCC – Tangerine Ballroom F3-4
Speaker: Samuel Yamshon, MD, Weill Cornell Medical College

Based on the premise that inhibition of EZH2 prevents T cell exhaustion and modulates T cell activity, the phase I study administered tazemetostat with CAR-T in patients with B-cell lymphoma. The combination resulted in an impressive 100% response rate with no signal of additional toxicity. BostonGene’s novel immunophenotyping is being performed to demonstrate the immune modulatory effects of combination therapy, providing mechanistic rationale for further combination approaches.

Research conducted in collaboration with Weill Cornell Medical Center

Poster presentations:

Abstract number: 1837
Title: Refining diffuse large B-cell lymphoma subtyping using Lymphly, an evidence-based classifier
Date & time: December 6 — 5:30 PM – 7:30 PM
Speaker: Nikita Kotlov, MS, BostonGene

BostonGene developed Lymphly, an AI hierarchical classifier for diffuse large B-cell lymphoma (DLBCL), to resolve genetically heterogeneous and atypical tumors often missed by existing classifications. By integrating pathway-relevant genomic alterations into a transparent framework, Lymphly distinguishes both established and emerging subtypes, including high-risk TP53+ and MYC+ groups, offering refined molecular stratification for clinical trial design, treatment selection and targeted therapy development.

Abstract number: 2692
Title: A genetic comparison of Epstein-Barr virus-associated polymorphic lymphoproliferative disorder and diffuse large B cell lymphoma
Date & time: December 6 — 5:30 PM – 7:30 PM
Speaker: Jennifer Chapman, MD, University of Miami and Sylvester Comprehensive Cancer Center

BostonGene’s multimodal platform with integrated genomic, transcriptomic and immune data was used to analyze and compare Epstein-Barr virus (EBV)-positive lymphoproliferative disorder and diffuse large B-cell lymphoma. This study underscored the complexity of EBV-driven diseases and highlighted the need for improved classification strategies, demonstrating the potential of BostonGene’s AI-powered platform to advance precision diagnostics and improve patient outcomes.

Research done in collaboration with the University of Miami Sylvester Cancer Institute

Abstract number: 12996
Title: An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma
Date & time: December 8 — 6:00 PM – 8:00 PM
Speaker: Joshua W.D. Tobin, MD, MSc, Princess Alexandra Hospital, Mater Research Institute

In collaboration with MD Anderson and several hospitals and academic institutions in Australia, BostonGene leveraged its multimodal pipeline to design a B cell-based candidate biomarker in patients with follicular lymphoma treated with bendamustine-based immunochemotherapy (ICT). Represented by centroblast (CB) scores, this biomarker identifies patients with high-grade disease who may respond to bendamustine-based ICT. Independent of and additive to pre-treatment PET, the CB score was highly prognostic suggesting a potential role for patient stratification.

Research done in collaboration with the University of Queensland

Online only

Title: Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma

BostonGene’s integrated platform, combining whole exome and RNA sequencing of tumor (CD138⁺ plasma cells) and peripheral blood samples, reproduced FISH-detectable abnormalities (e.g., del17p/TP53 deletion or t(11;14) translocations) and revealed additional mutations, structural variants and immune signatures in multiple myeloma patients, including low-tumor-content samples. By overcoming limitations of conventional FISH, BostonGene’s approach may provide a scalable solution and broader diagnostic capabilities for unified genomic and immune monitoring in clinical trials and patient care.

Research done in collaboration with the University of Miami Sylvester Cancer Institute

In addition to the poster presentations, the abstracts are published online in the November supplemental issue of Blood.

(Press release, BostonGene, NOV 25, 2025, View Source [SID1234660956])

On November 25, 2025 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 37th Annual Healthcare Conference, New York, NY

Format – Fireside chat and 1×1 investor meetings
Date and Time – Tuesday, Dec. 2, 2025 at 1:30pm ET

Evercore 8th Annual Healthcare Conference, Coral Gables, FL

Format – Fireside chat and 1×1 investor meetings
Date and Time – Wednesday, Dec. 3, 2025 at 7:55am ET
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at View Source Replays of the webcasts will be available for at least 30 days following the events.

(Press release, AnaptysBio, NOV 25, 2025, View Source [SID1234660941])

On November 25, 2025 enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, reported that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed on the "Events and Presentations" page under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days.

(Press release, enGene, NOV 25, 2025, View Source [SID1234660957])

On November 25, 2025 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

(Press release, Fate Therapeutics, NOV 25, 2025, View Source [SID1234660942])